抗菌薬感受性試験の世界市場予測(〜2025):製品別(手動式、自動式)、種類別(抗菌、抗真菌)、用途別(臨床診断)、方法別(ETEST、ディスク拡散)、エンドユーザー別

◆英語タイトル:Antimicrobial Susceptibility Testing Market by Product (Manual, Automated Susceptibility Testing System), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion), End-User - Global Forecasts to 2025
◆商品コード:MD 5931
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年10月27日
◆ページ数:215
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は抗菌薬感受性試験の世界市場が2020年32億ドルから2025年42億ドルまで、年平均5.5%成長すると予測しています。本調査レポートでは、抗菌薬感受性試験の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(手動式抗菌薬感受性試験製品、自動式実験器具、培養・増殖培地、消耗品)分析、種類別(抗菌薬感受性試験、抗真菌薬感受性試験、抗寄生虫薬感受性試験、その他)分析、用途別(臨床診断、創薬・開発、疫学、その他)分析、方法別(ディスク拡散、凝集、試験法、遺伝子型法)分析、エンドユーザー別(病院・診断センター、製薬・バイオテクノロジー企業、研究・学術機関、委託研究機関)分析、地域別分析、競争状況、企業評価・情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・抗菌薬感受性試験の世界市場規模:製品別(手動式抗菌薬感受性試験製品、自動式実験器具、培養・増殖培地、消耗品)
・抗菌薬感受性試験の世界市場規模:種類別(抗菌薬感受性試験、抗真菌薬感受性試験、抗寄生虫薬感受性試験、その他)
・抗菌薬感受性試験の世界市場規模:用途別(臨床診断、創薬・開発、疫学、その他)
・抗菌薬感受性試験の世界市場規模:方法別(ディスク拡散、凝集、試験法、遺伝子型法)
・抗菌薬感受性試験の世界市場規模:エンドユーザー別(病院・診断センター、製薬・バイオテクノロジー企業、研究・学術機関、委託研究機関)
・抗菌薬感受性試験の世界市場規模:地域別
・競争状況
・企業評価・情報
【レポートの概要】

“The antimicrobial susceptibility testing market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period.” Growth of the market is mainly attributed to the technological advancements; increasing incidences of infectious diseases, and growing public and private investments, funding, and grants are driving the global antimicrobial susceptibility testing market. However, complex regulatory frameworks that delay the approval of new microbial susceptibility tests is expected to challenge market growth to a certain extent.

“In terms of products, automated laboratory instruments segment to register significant growth during the forecast period.”
Based on the product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. Significant growth of the segment is attributed to the ongoing trend of laboratory automation among clinical laboratories, advantages offered by automated AST instruments over manual susceptibility instruments, and technological advancements in the market. Automated instruments offer a wide range of advantages over manual susceptibility testing products, such as reduced labor cost, shortened incubation time, and large-volume sample handling. These advantages offered by the automated systems have led to the growth of this segment.

“clinical diagnostics application segment is expected to witness the highest growth in the AST market, during the forecast period.”
Based on application, the antimicrobial susceptibility testing market has been segmented into the antimicrobial susceptibility testing market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and other applications. The growth in this market is attributed to the rising prevalence of infectious diseases, increasing incidence of HAIs, large target patient population base (especially in emerging countries), the growing procedural volume of clinical diagnostic tests, rising emphasis on effective and early disease diagnosis across major markets, and the introduction of various technologically advanced susceptibility testing products.

“diagnostic laboratories and hospitals segment is expected to account for the largest share of the AST market, by the end user”
On the basis of end-users, the antimicrobial susceptibility testing market has been segmented into diagnostic laboratories and hospitals, pharmaceutical and biotechnology companies, contract research organizations (CROs), and research and academic institutes. The growth of this segment is attributed to the significant number of antibacterial, antiparasitic, and antifungal tests procedures performed in diagnostic laboratories and hospitals; and the growing number of hospitals across major markets. Moreover, a growing trend towards the utilization of rapid AST platforms and improving healthcare expenditure in emerging markets will further boost the growth of this segment in the coming years.

“Asia Pacific market is expected to grow at the highest CAGR during the forecast period.”
The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period majorly due to the heavy burden of infectious diseases, rising healthcare expenditure, and increasing research into AST. Apart from this, the rising number of biotechnology and pharmaceutical companies in the APAC region is expected to propel the market for antimicrobial susceptibility testing.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3– 21%
• By Designation: C-level–47%, Director-level–33%, and Others–20%
• By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America–6%, and the Middle East & Africa–2%

Some of the prominent players in the antimicrobial susceptibility testing market include bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), Hi-Media Laboratories (India), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others.

Research Coverage
This report studies the AST market based on product, type, method, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the AST market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the AST market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the AST market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

【レポートの目次】

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 28
TABLE 1 INCLUSIONS & EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED FOR THE STUDY 29
1.4 CURRENCY USED FOR THE STUDY 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: RESEARCH METHODOLOGY STEPS 32
FIGURE 2 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Breakdown of primaries 36
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.1.2.2 Key data from primary sources 37
2.2 MARKET SIZE ESTIMATION 38
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 38
2.2.1 VENDOR REVENUE-BASED MARKET ESTIMATION 39
FIGURE 5 VENDOR REVENUE-BASED MARKET ESTIMATION 40
2.2.2 END USER-BASED MARKET SIZE ESTIMATION 40
FIGURE 6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: END USER-BASED ESTIMATION 41
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 7 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43

3 EXECUTIVE SUMMARY 44
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 44
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY TYPE,
2020 VS. 2025 45
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION,
2020 VS. 2025 (USD MILLION) 46
FIGURE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY METHOD, 2020 VS. 2025 (USD MILLION) 47
FIGURE 12 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY END USER, 2020 VS. 2025 47
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 48
4 PREMIUM INSIGHTS 49
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING: MARKET OVERVIEW 49
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE ARE THE MAJOR FACTORS DRIVING THE GROWTH OF THE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ACROSS THE GLOBE 49
4.2 GEOGRAPHIC ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020 VS 2025, (USD MILLION) 50
FIGURE 15 THE AUTOMATED LABORATORY INSTRUMENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2025 50
4.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020 VS 2025, (USD MILLION) 51
FIGURE 16 THE SUSCEPTIBILITY TESTING DISKS SUBSEGMENT IS EXPECTED TO DOMINATE THE MARKET, BY TYPE, DURING THE FORECAST PERIOD 51
4.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION AND TYPE 52
FIGURE 17 ANTIFUNGAL SUSCEPTIBILITY TESTING SEGMENT TO REGISTER SIGNIFICANT GROWTH IN THE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET IN EUROPE 52
4.5 GEOGRAPHIC ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD AND REGION, 2020 VS 2025, (USD MILLION) 53
FIGURE 18 THE AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS SEGMENT TO WITNESS HIGH GROWTH IN THE APAC MARKET DURING THE FORECAST PERIOD 53
4.6 GEOGRAPHIC SNAPSHOT OF THE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 54
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 20 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Rising incidence of infectious diseases coupled with epidemic & pandemic events 56
5.2.1.2 Increasing funding, research grants, and public-private investments in the market 57
5.2.1.3 Technological advancements 57
5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species 59
5.2.1.5 Emergence of multidrug-resistance due to drug abuse 60
5.2.2 RESTRAINTS 61
5.2.2.1 High cost of automated ID/AST systems 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 Emerging markets 61
5.2.3.2 Awareness initiatives for antimicrobial resistance and its control 62
5.2.4 CHALLENGES 63
5.2.4.1 Complex regulatory frameworks that delay antimicrobial testing approvals 63
5.3 IMPACT OF THE COVID-19 ON THE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 63
5.4 ECOSYSTEM ANALYSIS 64
FIGURE 21 ECOSYSTEM ANALYSIS OF THE OVERALL AST MARKET 64
5.5 VALUE CHAIN ANALYSIS 65
FIGURE 22 VALUE CHAIN ANALYSIS: MAXIMUM VALUE-ADDED DURING MANUFACTURING PHASE 65
5.6 REGULATORY ANALYSIS 65
5.6.1 NORTH AMERICA 65
5.6.1.1 US 65
TABLE 2 US FDA: MEDICAL DEVICE CLASSIFICATION 66
TABLE 3 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
5.6.1.2 Canada 67
TABLE 4 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 67
FIGURE 23 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 68
5.6.2 EUROPE 69
FIGURE 24 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR) 70
5.6.3 ASIA PACIFIC 71
5.6.3.1 Japan 71
TABLE 5 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 71
5.6.3.2 China 72
TABLE 6 CHINA: CLASSIFICATION OF MEDICAL DEVICES 72
5.6.3.3 India 73

6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT 74
6.1 INTRODUCTION 75
TABLE 7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 75
6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 75
TABLE 8 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 75
TABLE 9 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY REGION, 2018–2025 (USD MILLION) 76
6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 76
TABLE 10 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, 2018–2025 (USD MILLION) 76
6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 77
TABLE 11 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 77
6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY METHOD, 2018–2025 (USD MILLION) 77
TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY METHOD, 2018–2025 (USD MILLION) 77
6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY END USER, 2018–2025 (USD MILLION) 78
TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,
BY END USER, 2018–2025 (USD MILLION) 78
6.2.5 SUSCEPTIBILITY TESTING DISKS 78
6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth 78
TABLE 14 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION,
2018–2025 (USD MILLION) 79
6.2.5.2 Susceptibility testing disks market, by type,
2018–2025 (USD million) 79
TABLE 15 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE,
2018–2025 (USD MILLION) 79
6.2.5.3 Susceptibility testing disks market, by application,
2018–2025 (USD million) 80
TABLE 16 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 80
6.2.5.4 Susceptibility testing disks market, by method,
2018–2025 (USD million) 80
TABLE 17 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD,
2018–2025 (USD MILLION) 80
6.2.5.5 Susceptibility testing disks market, by end user,
2018–2025 (USD million) 81
TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER,
2018–2025 (USD MILLION) 81
6.2.6 MIC STRIPS 81
6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth 81
TABLE 19 MIC STRIPS MARKET, BY REGION, 2018–2025 (USD MILLION) 82
6.2.6.2 MIC strips market, by type, 2018–2025 (USD million) 82
TABLE 20 MIC STRIPS MARKET, BY TYPE, 2018–2025 (USD MILLION) 82
6.2.6.3 MIC strips market, by application, 2018–2025 (USD million) 83
TABLE 21 MIC STRIPS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 83
6.2.6.4 MIC strips market, by method, 2018–2025 (USD million) 83
TABLE 22 MIC STRIPS MARKET, BY METHOD, 2018–2025 (USD MILLION) 83
6.2.6.5 MIC STRIPS MARKET, BY END USER, 2018–2025 (USD MILLION) 84
TABLE 23 MIC STRIPS MARKET, BY END USER, 2018–2025 (USD MILLION) 84
6.2.7 SUSCEPTIBILITY TESTING PLATES 84
6.2.7.1 Growing adoption of automated/rapid AST systems is hampering the growth of this segment 84
TABLE 24 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION,
2018–2025 (USD MILLION) 85
6.2.7.2 Susceptibility testing plates market, by type,
2018–2025 (USD million) 85
TABLE 25 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 85
6.2.7.3 Susceptibility testing plates market, by application,
2018–2025 (USD million) 86
TABLE 26 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 86
6.2.7.4 Susceptibility testing plates market, by method,
2018–2025 (USD million) 86
TABLE 27 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD,
2018–2025 (USD MILLION) 86
6.2.7.5 Susceptibility testing plates market, by end user,
2018–2025 (USD million) 87
TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER,
2018–2025 (USD MILLION) 87
6.3 AUTOMATED LABORATORY INSTRUMENTS 87
6.3.1 THE ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES WILL FUEL SEGMENT GROWTH 87
TABLE 29 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 88
6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 89
TABLE 30 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 89
6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 89
TABLE 31 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 89
6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD,
2018–2025 (USD MILLION) 90
TABLE 32 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD,
2018–2025 (USD MILLION) 90
6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER,
2018–2025 (USD MILLION) 90
TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER,
2018–2025 (USD MILLION) 90
6.4 CULTURE AND GROWTH MEDIA 90
6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE THE SEGMENT GROWTH 90
TABLE 34 CULTURE AND GROWTH MEDIA MARKET, BY REGION,
2018–2025 (USD MILLION) 91
6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 35 CULTURE AND GROWTH MEDIA MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 92
TABLE 36 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 92
6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD,
2018–2025 (USD MILLION) 92
TABLE 37 CULTURE AND GROWTH MEDIA MARKET, BY METHOD,
2018–2025 (USD MILLION) 92
6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER,
2018–2025 (USD MILLION) 93
TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY END USER,
2018–2025 (USD MILLION) 93
6.5 CONSUMABLES 93
6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT THE CONSUMABLES SEGMENT 93
TABLE 39 CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION) 94
6.5.2 CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 40 CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
6.5.3 CONSUMABLES MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 95
TABLE 41 CONSUMABLES MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 95
6.5.4 CONSUMABLES MARKET, BY METHOD, 2018–2025 (USD MILLION) 95
TABLE 42 CONSUMABLES MARKET, BY METHOD, 2018–2025 (USD MILLION) 95
6.5.5 CONSUMABLES MARKET, BY END USER, 2018–2025 (USD MILLION) 96
TABLE 43 CONSUMABLES MARKET, BY END USER, 2018–2025 (USD MILLION) 96
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 97
7.1 INTRODUCTION 98
TABLE 44 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 98
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING 98
7.2.1 THE EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS 98
TABLE 45 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION) 99
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING 99
7.3.1 INCREASING CANDIDA AND ASPERGILLUS SPECIES FUNGAL INFECTIONS ARE MAJOR FACTORS DRIVING SEGMENT GROWTH 99
TABLE 46 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN THE UNITED STATES FOR FY 2017 100
TABLE 47 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION) 100
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING 101
7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE SEGMENT GROWTH FOR PRODUCTS 101
TABLE 48 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018–2025 (USD MILLION) 102
7.5 OTHER SUSCEPTIBILITY TESTING TYPES 102
7.5.1 COMPLEXITY ASSOCIATED WITH FASTIDIOUS PATHOGEN TESTING TO HAMPER THE GROWTH OF THIS SEGMENT 102
TABLE 49 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER SUSCEPTIBILITY TESTING TYPES, BY REGION, 2018–2025 (USD MILLION) 102
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 103
8.1 INTRODUCTION 104
TABLE 50 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 104
8.2 CLINICAL DIAGNOSTICS 104
8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED DRIVE SEGMENT GROWTH 104
TABLE 51 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2025 (USD MILLION) 105
8.3 DRUG DISCOVERY AND DEVELOPMENT 105
8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH 105
TABLE 52 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018–2025 (USD MILLION) 106
8.4 EPIDEMIOLOGY 106
8.4.1 OUTBREAK OF PANDEMIC AND EPIDEMIC SITUATIONS TO DRIVE DEMAND FOR AST PRODUCTS 106
TABLE 53 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY,
BY REGION, 2018–2025 (USD MILLION) 107
8.5 OTHER APPLICATIONS 107
8.5.1 GROWING ADOPTION OF AST PRODUCTS FOR BIOTERRORISM SURVEILLANCE TO FUEL SEGMENT GROWTH 107
TABLE 54 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 108

9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD 109
9.1 INTRODUCTION 110
TABLE 55 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD,
2018–2025 (USD MILLION) 110
9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING INSTRUMENTS 110
9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE SEGMENT GROWTH 110
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018–2025 (USD MILLION) 112
9.3 DISK DIFFUSION 112
9.3.1 RISING INCIDENCES OF URINARY TRACT INFECTIONS TO DRIVE SEGMENT GROWTH 112
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION,
BY REGION, 2018–2025 (USD MILLION) 113
9.4 AGAR DILUTION 113
9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY 113
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AGAR DILUTION,
BY REGION, 2018–2025 (USD MILLION) 114
9.5 ETEST METHOD 114
9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION HAMPERS THE ADOPTION OF THIS METHOD 114
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST METHOD,
BY REGION, 2018–2025 (USD MILLION) 115
9.6 GENOTYPIC METHODS 115
9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT SEGMENT GROWTH 115
TABLE 60 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR GENOTYPIC METHODS, BY REGION, 2018–2025 (USD MILLION) 116
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 117
10.1 INTRODUCTION 118
TABLE 61 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 118
10.2 HOSPITALS AND DIAGNOSTIC CENTERS 118
10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES COUPLED WITH THE RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE SEGMENT GROWTH 118
TABLE 62 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018–2025 (USD MILLION) 119
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 120
10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH 120
FIGURE 25 ANTIMICROBIAL RESISTANCE RELATED R&D PROJECTS BY KEY PLAYERS, 2020 120
TABLE 63 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION) 120
10.4 RESEARCH & ACADEMIC INSTITUTES 121
10.4.1 GROWING RESEARCH GRANTS AND FUNDING IS ACCELERATING THE GROWTH OF THIS SEGMENT 121
TABLE 64 FUNDING BY THE DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020 122
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 122
10.5 CONTRACT RESEARCH ORGANIZATIONS 123
10.5.1 CLINICAL TRIAL GLOBALIZATION AND THE GROWING NUMBER OF CROS IN EMERGING ECONOMIES DRIVES MARKET GROWTH 123
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION) 123
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 124
11.1 INTRODUCTION 125
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION,
2018–2025 (USD MILLION) 125
11.2 NORTH AMERICA 125
FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 126
TABLE 68 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 127
TABLE 69 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY PRODUCT 2018–2025 (USD MILLION) 127
TABLE 70 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 127
TABLE 71 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 128
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 128
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY METHOD, 2018–2025 (USD MILLION) 129
TABLE 74 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY END USER, 2018–2025 (USD MILLION) 129
11.2.1 US 129
11.2.1.1 The US dominated the North American AST market in 2019 129
TABLE 75 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 131
TABLE 76 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 131
11.2.2 CANADA 131
11.2.2.1 Favorable government initiatives to market growth during the forecast period 131
TABLE 77 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 132
TABLE 78 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 133
11.3 EUROPE 133
TABLE 79 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 133
TABLE 80 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT 2018–2025 (USD MILLION) 134
TABLE 81 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 134
TABLE 82 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 135
TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 135
TABLE 84 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2018–2025 (USD MILLION) 136
TABLE 85 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 136
11.3.1 GERMANY 136
11.3.1.1 Germany dominated the European antimicrobial susceptibility testing market in 2019 136
TABLE 86 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 137
TABLE 87 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 137
11.3.2 FRANCE 138
11.3.2.1 Supportive government policies and easy accessibility to healthcare services to fuel market growth in France 138
TABLE 88 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 139
TABLE 89 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 139
11.3.3 UK 139
11.3.3.1 The significant prevalence of infectious diseases coupled with increasing awareness for AST products to drive market growth 139
TABLE 90 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT.
2018–2025 (USD MILLION) 140
TABLE 91 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 140
11.3.4 ITALY 141
11.3.4.1 Increasing R&D investments by pharmaceutical companies will propel the demand for AST products in Italy 141
TABLE 92 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 141
TABLE 93 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 142
11.3.5 SPAIN 142
11.3.5.1 Rising geriatric population in Spain to drive market growth for AST procedures 142
TABLE 94 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 143
TABLE 95 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 143
11.3.6 REST OF EUROPE (ROE) 143
TABLE 96 ROE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 144
TABLE 97 ROE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 144
11.4 ASIA PACIFIC 145
FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 146
TABLE 98 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 147
TABLE 99 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY PRODUCT, 2018–2025 (USD MILLION) 147
TABLE 100 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 148
TABLE 101 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 148
TABLE 102 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 149
TABLE 103 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY METHOD, 2018–2025 (USD MILLION) 149
TABLE 104 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY END USER, 2018–2025 (USD MILLION) 150
11.4.1 JAPAN 150
11.4.1.1 Rising initiatives for the development of innovative screening technologies and growing geriatric population to drive market growth in Japan 150
TABLE 105 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 151
TABLE 106 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 151
11.4.2 CHINA 151
11.4.2.1 Favorable government regulations and the heavy burden of infectious diseases to drive market growth in China 151
FIGURE 28 INCIDENTS OF INFECTIOUS DISEASES IN CHINA, 2019 152
TABLE 107 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 152
TABLE 108 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 153
11.4.3 INDIA 153
11.4.3.1 Growing initiatives for clinical diagnosis by the government and major players in the market to drive market growth 153
TABLE 109 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 154
TABLE 110 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 154
11.4.4 AUSTRALIA 155
11.4.4.1 Increasing government funding for research activities to deliver novel products drives the market growth 155
TABLE 111 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 155
TABLE 112 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 156
11.4.5 SOUTH KOREA 156
11.4.5.1 The requirement of rapid AMR detection to drive the automated AST systems segment in South Korea 156
TABLE 113 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY PRODUCT, 2018–2025 (USD MILLION) 157
TABLE 114 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 157
11.4.6 REST OF ASIA PACIFIC 157
TABLE 115 ROAPAC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 158
TABLE 116 ROAPAC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 158
11.5 LATIN AMERICA 158
TABLE 117 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 159
TABLE 118 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY PRODUCT, 2018–2025 (USD MILLION) 159
TABLE 119 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 160
TABLE 120 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 160
TABLE 121 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 161
TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY METHOD, 2018–2025 (USD MILLION) 161
TABLE 123 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY END USER, 2018–2025 (USD MILLION) 162
11.5.1 BRAZIL 162
11.5.1.1 The established presence of major AST product manufacturers drives the market growth in Brazil 162
TABLE 124 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 163
TABLE 125 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 163
11.5.2 MEXICO 163
11.5.2.1 The growing economic development of the country draws increasing investments, thus driving market growth 163
TABLE 126 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 164
TABLE 127 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 164
11.5.3 REST OF LATIN AMERICA 165
TABLE 128 ROLATAM: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 165
TABLE 129 ROLATAM: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 165
11.6 MIDDLE EAST & AFRICA 166
11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH 166
TABLE 130 MEA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 166
TABLE 131 MEA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, 2018–2025 (USD MILLION) 167
TABLE 132 MEA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 167
TABLE 133 MEA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 168
TABLE 134 MEA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2018–2025 (USD MILLION) 168
TABLE 135 MEA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 169
12 COMPETITIVE LANDSCAPE 170
12.1 INTRODUCTION 170
12.2 MARKET SHARE ANALYSIS 170
FIGURE 29 GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE,
BY KEY PLAYER, 2019 170
12.3 COMPETITIVE SCENARIO 171
12.3.1 PRODUCT LAUNCHES AND APPROVALS 171
12.3.2 ACQUISITIONS 172
12.3.3 AGREEMENTS AND COLLABORATIONS 173
12.3.4 EXPANSIONS 173
13 COMPANY EVOLUTION MATRIX AND COMPANY PROFILES 174
13.1 COMPETITIVE EVOLUTION MATRIX AND METHODOLOGY 174
13.1.1 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2019) 174
13.1.1.1 Visionary leaders 174
13.1.1.2 Innovators 174
13.1.1.3 Dynamic differentiators 175
13.1.1.4 Emerging companies 175
FIGURE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 (OVERALL MARKET) 175
13.1.2 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2019) 176
13.1.2.1 Progressive companies 176
13.1.2.2 Starting blocks 176
13.1.2.3 Responsive companies 176
13.1.2.4 Dynamic companies 176
FIGURE 31 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 (SME/START-UPS) 177
13.2 COMPANY PROFILES 178
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.2.1 BIOMÉRIEUX SA 178
FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT 178
13.2.2 BECTON, DICKINSON AND COMPANY 181
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 181
13.2.3 THERMO FISHER SCIENTIFIC 183
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 183
13.2.4 DANAHER CORPORATION 186
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT 186
13.2.5 BIO-RAD LABORATORIES, INC. 188
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 188
13.2.6 BRUKER 190
FIGURE 37 BRUKER: COMPANY SNAPSHOT 190
13.2.7 ROCHE DIAGNOSTICS 192
FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 192
13.2.8 MERCK KGAA 194
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT 194
13.2.9 ACCELERATE DIAGNOSTICS, INC. 196
FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT 196
13.2.10 HIMEDIA LABORATORIES 198
13.2.11 LIOFILCHEM S.R.L. 200
13.2.12 ALIFAX S.R.L. 202
13.2.13 CREATIVE DIAGNOSTICS 204
13.2.14 SYNBIOSIS 206
13.2.15 BIOANALYSE 207
13.2.16 OTHER COMPANIES 208
13.2.16.1 ZHUHAI DL BIOTECH Co., Ltd. 208
13.2.16.2 ELITechGroup 209
13.2.16.3 Mast Group Ltd. 210
13.2.16.4 CONDALAB 211
13.2.16.5 Genefluidics, Inc. 211
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 212
14.1 DISCUSSION GUIDE 212
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 217
14.3 AVAILABLE CUSTOMIZATIONS 219
14.4 RELATED REPORTS 219
14.5 AUTHOR DETAILS 220



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗菌薬感受性試験の世界市場予測(〜2025):製品別(手動式、自動式)、種類別(抗菌、抗真菌)、用途別(臨床診断)、方法別(ETEST、ディスク拡散)、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆